Drug Profile
Estradiol valerate/dienogest - Bayer HealthCare Pharmaceutials
Alternative Names: Climodien; Climodiène; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; LafammeLatest Information Update: 18 Feb 2019
Price :
$50
*
At a glance
- Originator Jenapharm
- Developer Bayer HealthCare Pharmaceuticals
- Class Estradiol congeners; Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis
- No development reported Acne
- Discontinued Pregnancy
Most Recent Events
- 18 Feb 2019 No recent reports of development identified after preregistration for Acne (Treatment-resistant) in European Union (PO)
- 27 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for estradiol valerate/dienogest for Acne (treatment-resistant) in European Union
- 31 Dec 2016 Preregistration for Acne (Treatment-resistant) in European Union (PO)